OS rates of patients by age from US centers who underwent allogeneic HSCT for SCD registered at CIBMTR
| . | HLA-identical sibling (n = 674) . | HLA-matched other relative (n = 25) . | HLA-mismatched relative (n = 101) . | Other relative (n = 5) . | Unrelated donor (n = 175) . | Cord blood (n = 109) . | All (N = 1089) . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | N evaluated . | OS (95% CI), % . | N evaluated . | OS (95% CI), %; or patients alive (%)* . | N evaluated . | OS (95% CI), % . | N evaluated . | Patients alive (%) . | N evaluated . | OS (95% CI), % . | N evaluated . | OS (95% CI), %; or patients alive (%)* . | N evaluated . | OS (95% CI), % . |
| Age <16 y | 500 | 17 | 41 | 3† | 120 | 92 | 773 | |||||||
| 100 d | 99 (98-100) | 88 (69-99) | 100 | 3 (100) | 94 (89-98) | 98 (94-100) | 98 (97-99) | |||||||
| 6 mo | 98 (97-99) | 88 (69-99) | 100 | 3 (100) | 91 (85-95) | 96 (90-99) | 96 (95-98) | |||||||
| 1 y | 97 (95-98) | 88 (69-99) | 97 (89-100) | 3 (100) | 89 (82-94) | 93 (87-98) | 95 (94-97) | |||||||
| 2 y | 95 (93-97) | 88 (69-99) | 90 (76-98) | 2 (67) | 85 (77-91) | 88 (81-94) | 92 (90-94) | |||||||
| Age ≥16 y | 139 | 6† | 50 | 2† | 47 | 13† | 257 | |||||||
| 100 d | 99 (96-100) | 6 (100) | 98 (92-100) | 2 (100) | 96 (88-100) | 10 (77) | 97 (94-99) | |||||||
| 6 mo | 96 (93-99) | 5 (83) | 94 (85-99) | 1 (50) | 89 (78-96) | 8 (62) | 93 (89-96) | |||||||
| 1 y | 92 (87-96) | 4 (66) | 89 (78-96) | 1 (50) | 76 (62-88) | 8 (62) | 87 (83-91) | |||||||
| 2 y | 87 (80-92) | 3 (50) | 86 (74-95) | 1 (50) | 64 (47-80) | 7 (53) | 82 (76-86) | |||||||
| . | HLA-identical sibling (n = 674) . | HLA-matched other relative (n = 25) . | HLA-mismatched relative (n = 101) . | Other relative (n = 5) . | Unrelated donor (n = 175) . | Cord blood (n = 109) . | All (N = 1089) . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | N evaluated . | OS (95% CI), % . | N evaluated . | OS (95% CI), %; or patients alive (%)* . | N evaluated . | OS (95% CI), % . | N evaluated . | Patients alive (%) . | N evaluated . | OS (95% CI), % . | N evaluated . | OS (95% CI), %; or patients alive (%)* . | N evaluated . | OS (95% CI), % . |
| Age <16 y | 500 | 17 | 41 | 3† | 120 | 92 | 773 | |||||||
| 100 d | 99 (98-100) | 88 (69-99) | 100 | 3 (100) | 94 (89-98) | 98 (94-100) | 98 (97-99) | |||||||
| 6 mo | 98 (97-99) | 88 (69-99) | 100 | 3 (100) | 91 (85-95) | 96 (90-99) | 96 (95-98) | |||||||
| 1 y | 97 (95-98) | 88 (69-99) | 97 (89-100) | 3 (100) | 89 (82-94) | 93 (87-98) | 95 (94-97) | |||||||
| 2 y | 95 (93-97) | 88 (69-99) | 90 (76-98) | 2 (67) | 85 (77-91) | 88 (81-94) | 92 (90-94) | |||||||
| Age ≥16 y | 139 | 6† | 50 | 2† | 47 | 13† | 257 | |||||||
| 100 d | 99 (96-100) | 6 (100) | 98 (92-100) | 2 (100) | 96 (88-100) | 10 (77) | 97 (94-99) | |||||||
| 6 mo | 96 (93-99) | 5 (83) | 94 (85-99) | 1 (50) | 89 (78-96) | 8 (62) | 93 (89-96) | |||||||
| 1 y | 92 (87-96) | 4 (66) | 89 (78-96) | 1 (50) | 76 (62-88) | 8 (62) | 87 (83-91) | |||||||
| 2 y | 87 (80-92) | 3 (50) | 86 (74-95) | 1 (50) | 64 (47-80) | 7 (53) | 82 (76-86) | |||||||
CIBMTR, Center for International Blood and Marrow Transplant Research.
OS for age <16 rows and age ≥16 rows on “HLA-identical sibling,” “HLA-mismatched relative,” and “Unrelated donor.” Patient alive for age ≥16, “HLA-matched other relative,” “Other relative,” and “Cord blood.”
Number too small to calculate overall survival rate. Number of patients alive is presented.